26Sep/13

Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to … – PR Newswire (press release)

Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to
PR Newswire (press release)
In February 2011, Roche began a Phase 3 registration trial of subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and submitted a line extension 

and more »

26Sep/13

74% young Hyderabadis old at heart – Times of India


Economic Times

74% young Hyderabadis old at heart
Times of India
HYDERABAD: A staggering 74% of Hyderabadis in their thirties and early forties stood a high risk of developing heart disease as against Mumbai’s 72% and Delhi’s 71%, according to one of India’s biggest studies conducted over a period three years.
Work force in 30-44 age group high on heart disease risk: StudyEconomic Times

all 5 news articles »